<div id="readability-page-1"><div><p><span>Egetis Therapeutics AB (publ) </span><span>:</span></p><ul><li>COMPLETES THE U.S. ROLLING NDA SUBMISSION FOR EMCITATE® (TIRATRICOL) FOR TREATMENT OF MCT8 DEFICIENCY</li><li>ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026</li></ul></div></div>

<p>Egetis Therapeutics AB (publ) :COMPLETES THE U.S. ROLLING NDA SUBMISSION FOR EMCITATE® (TIRATRICOL) FOR TREATMENT OF MCT8 DEFICIENCYANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026</p>

Reuters

ESC NEUBASE THERAPEUTI

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Global Healthcare

Entero Therapeutics

Health Care Select Sector SPDR

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Atara Biotherap

VG Health

iShares US Pharma

Egetis Completes U.S. Rolling NDA Submission For Emcitate